[1]
Fonseca, P.E.O. et al. 2024. Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks. Archives of Pharmacy and Pharmaceutical Sciences. 8, 1 (May 2024), 041–046. DOI:https://doi.org/10.29328/journal.apps.1001055.